Zeneca Agrees to Purchase 50% Interest in Salick Health Care, Inc.

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 1
Volume 4
Issue 1

LONDON, UK--As Oncology News International (ONI) went to press, we received news that Zeneca Group PLC has agreed to buy a 50% interest in Salick Health Care, Inc (Los Angeles). The agreement is subject to shareholder approval and US regulatory review, the company said.

LONDON, UK--As Oncology News International (ONI) went to press,we received news that Zeneca Group PLC has agreed to buy a 50%interest in Salick Health Care, Inc (Los Angeles). The agreementis subject to shareholder approval and US regulatory review, thecompany said.

Salick Health Care operates 10 comprehensive cancer care centers,offers specialized inpatient and outpatient services through itssubsidiaries, and operates SalickNet, a managed care subsidiary.

A full report on the agreement will appear in the February, 1995,issue of Oncology News International.

Articles in this issue
MDs Fear Managed Care Equals Lower-Quality Care
Dallas Medical Center Launches Umbilical Stem Cell Project
Navelbine Receives FDA Approval for Advanced Non-Small -Cell Lung Cancer
European Trials Show Dose-Related Efficacy of Docetaxel In Metastatic Breast Cancer, Value of Steroid Pretreatment
Ethyol Approved for Use in the UK
Success of Breast Conserving Surgery Is Not Diminished in Community Setting
Assessment Tools Are Essential to Improve Management of Pain
Undertreating Pain Costs Money in the Long Run, Physician Warns
After 5 Years as Head, Dr. Broder Plans to Resign His Post at NCI
EORTC Endometrial Ca Trial Challenges Findings From GOG
Heterosexual AIDS Cases Up Sharply, But Numbers Remain Small
Antibiotic Regimen Leads to Lymphoma Regression
Look for Incremental Insurance Reform Steps With New Congress
Court Upholds Patents on AZT
Advances Reported in Phase I/II Trials of Radioimmunotherapy for Breast Cancer
Recent Videos
Extended follow-up for individuals with H3 K27M-mutated diffuse midline glioma may help explain the duration of response across patient subgroups.
Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, described the excitement of seeing novel molecules like antibody drug conjugates become more prominent.
Ronald Bleday, MD, credits a chronic pain clinic for consulting patients who may be at a greater risk for prolonged opioid use following surgery.
4 experts in this video
4 experts in this video
5 experts are featured in this series
Ronald Bleday, MD, stated that before standardizing a stepwise approach to treating surgical pain, providers might have overtreated patients with opioids.
Related Content
The EC decision is based on phase 3 DeFi trial results, in which nirogacestat met the primary end point of PFS in patients with progressing desmoid tumors.

Nirogacestat Receives European Approval for Treatment of Desmoid Tumors

Roman Fabbricatore
August 18th 2025
Article

The EC decision is based on phase 3 DeFi trial results, in which nirogacestat met the primary end point of PFS in patients with progressing desmoid tumors.

Beyond the Tumor: Addressing Body Image in Oncology

Beyond the Tumor: Addressing Body Image in Oncology

Daniel C. McFarland, DO;Michelle Fingeret, PhD
August 18th 2025
Podcast

Daniel C. McFarland, DO, and Michelle Fingeret, PhD, discuss the issue of body image in patients with cancer.

Patients with muscle-invasive bladder cancer with a positive Signatera test displayed a significant improvement in disease-free and overall survival.

ctDNA Test is Predictive of Adjuvant Atezolizumab Benefit in MIBC

Roman Fabbricatore
August 18th 2025
Article

Patients with muscle-invasive bladder cancer with a positive Signatera test displayed a significant improvement in disease-free and overall survival.

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 14th 2025
Podcast

The latest in first- and second-line therapies for bladder cancer, including trial data, AE management, and the role of molecular testing, were discussed in the latest Oncology Decoded podcast.

Outcomes favoring robotic surgery for CRC may be influenced by patient selection factors, including clinical stability.

Robotic Surgery Exhibits Benefit in Select Colorectal Cancer Procedures

Roman Fabbricatore
August 17th 2025
Article

Outcomes favoring robotic surgery for CRC may be influenced by patient selection factors, including clinical stability.

Data suggest that sotorasib plus panitumumab may represent a valuable new treatment option in this KRAS G12C-mutated colorectal cancer population.

Sotorasib Combo Improves Patient-Reported Outcomes in KRAS G12C+ CRC

Russ Conroy
August 17th 2025
Article

Data suggest that sotorasib plus panitumumab may represent a valuable new treatment option in this KRAS G12C-mutated colorectal cancer population.